Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986224 in Healthy Subjects and Chronic Heart Failure
NCT03281122Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing BMS-986224 with Placebo (2 arms). Primary endpoints: Number of Serious Adverse Events, Number of Adverse Events and 1 more. Started Sep 2017; status: terminated.
02
Drugs
BMS-986224
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03281122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281122.